Diligence Report – CGT Technology Assessment
Leading Private Equity Firm – Global
The Brief
A global private equity firm engaged us to produce a bespoke diligence report assessing the competitive and scientific landscape of ex vivo gene-modified natural killer (NK) cell therapies. The mandate was to provide clarity on clinical progress, manufacturing scalability, and leadership depth across both developers and CDMOs in order to support an upcoming investment decision.
The Challenge
The investor required a balanced, data-driven perspective that could bridge technical detail with commercial insight. The challenge was to map competitors, identify clinical bottlenecks, and evaluate leadership teams with enough precision to inform a multi-hundred-million-dollar transaction. At the same time, the analysis needed to remain objective and defensible, avoiding hype in a therapeutic area where early clinical results often outpace the underlying manufacturing and organizational readiness.
Our Approach
We built a structured intelligence report that evaluated pipeline maturity across both leading and emerging NK developers, assessed manufacturing readiness and CDMO capacity specific to allogeneic NK therapies, and benchmarked executive and scientific leadership teams against industry norms. The work also included a competitive SWOT and risk analysis, highlighting not only scientific momentum but also operational and organizational vulnerabilities. To strengthen the analysis, we supplemented desk research with curated expert interviews and a review of recent deal activity, ensuring the client received a perspective grounded in both current data and real-world context.
Outcome
The diligence package became a central input to the client’s investment committee discussion and directly influenced the decision to proceed with term sheet negotiations. The firm credited our insights on manufacturing risk and leadership gaps as critical differentiators that shaped their strategy. By delivering a balanced view of opportunity and risk, the report gave the investment team confidence to engage at scale while anticipating challenges that could affect long-term value creation.
Explore More Success Stories
VP Partnerships - Analytics Software Company (Global)
Analytics Software Company Partnerships Expansion
Recruited a VP Partnerships who signed three global alliance agreements and doubled partner-sourced pipeline within six months.
Head of Business Development - Life Sciences SaaS (Europe)
Life Sciences SaaS Commercial Expansion
Placed a Head of Business Development who drove €4M in new ARR and expanded global partnerships for a Life Sciences SaaS platform.
General Manager – USA
European Specialty CDMO Expansion
Placed founding US GM to establish operations and secure first American clients
Market Sizing Project – CGT Manufacturing Services
Advanced Therapies – USA
Provided market sizing analysis for US cell therapy manufacturing capacity
Diligence Report – CGT Technology Assessment
Leading Private Equity Firm – Global
Delivered market intelligence on ex vivo gene-modified NK cell therapies
Chief Scientific Officer
Gene Editing Biotech – Europe
Advanced platform from discovery to preclinical pipeline readiness
VP of Technical Operations
Specialty Biologics CDMO – USA
Enabled facility scale-up and tech transfers for new biologics programs
Let’s Create Your Success Story
Partner with us to find the leaders who drive lasting impact
Sanderson House,
22 Station Road, Horsforth, Leeds.
LS18 5NT.
United Kingdom